Adjuvant therapy for colon cancer: genes, genes... and the patient in the center

20-abr-2018 | Revista: Clinical Cancer Research

Rodriguez J (1), Vicent S (2), Chopitea A (1), Ponz-Sarvise M (3).

RESUMEN

Although molecular subtype-based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from FFPE specimens should be considered in order to create combined models that better define individual patients needs.

CITA DEL ARTÍCULO Clin Cancer Res. 2018 Apr 20. pii: clincanres.0818.2018. doi: 10.1158/1078-0432.CCR-18-0818

ver publicación en pubmed

Nuestros autores

Dr. Silvestre Vicent Cambra Ver Curriculum

Investigador | Investigador principal Programa de Investigación en Tumores Sólidos

Imagen del Dr. Mariano Ponz Sarvise, oncólogo médico de la Clínica Universidad de Navarra

Dr. Mariano Ponz-Sarvisé Ver Curriculum

Investigador Clínico Programa de Investigación en Tumores Sólidos